Yabao Pharmaceutical

Yabao Pharmaceutical Group Co., Ltd. integrates pharmaceutical research and development, production, and logistics. It is the first listed pharmaceutical company in Shanxi Province's pharmaceutical industry and one of the first recognized high-tech enterprises, ranking among the top 50 Chinese patent medicine enterprises. The "Yabao" trademark is a well-known trademark in China. The company has 5 branches and 13 subsidiaries, with over 6,000 employees. Its total assets amount to 2.4 billion yuan, with annual sales revenue of 1.5 billion yuan and annual profits and taxes of 300 million yuan, and it ranks among the top 50 Chinese patent medicine enterprises.
The company's main products include Chinese and Western medicine preparations, active pharmaceutical ingredients, and pharmaceutical packaging materials, totaling over 300 varieties. It has formed strong brands in cardiovascular and cerebrovascular disease medications and women's and children's medications. Among them, the patented product Dinggui'er Umbilical Patch is exclusively produced domestically, is a landmark brand product of Shanxi Province, renowned both domestically and internationally, and exported to Southeast Asian countries. The sales volumes of Zhenju Hypotensive Tablets, Troxerutin Tablets, Nimodipine Tablets, and Compound Reserpine Tablets are all national leaders.
The company has strong scientific research capabilities and has established research and development institutions such as a national-level enterprise technology center, Beijing Pharmaceutical Research Institute, and Taiyuan Pharmaceutical Research Center, forming a three-dimensional R&D system. There are nearly 100 professional R&D personnel with master's or doctoral degrees. A postdoctoral research workstation has been established in Beijing, focusing on modern Chinese medicine, biopharmaceuticals, and novel drug delivery systems for chemical drugs. The company has obtained 29 invention patent certificates and over 70 utility model patent certificates. Currently, more than 80 projects are under development, mainly national Class I and II new drugs featuring internationally advanced sustained-release and controlled-release formulations, biological preparations, and nano-targeted formulations.
The company's eight major production bases in operation have all passed national GMP certification, with strict quality supervision and control systems established according to GMP requirements. Each base is equipped with internationally advanced quality testing equipment, and internal quality control standards higher than national statutory standards have been established for each product to ensure drug quality. The newly built Beijing biopharmaceutical and Fenglingdu Industrial Park sustained-release and controlled-release formulation production lines, with a total investment of over 500 million yuan, are constructed entirely in accordance with US FDA and EU cGMP standards. Their products will be sold to high-end European and American markets, with annual exports expected to reach nearly 200 million US dollars.
Depending on different drug types and key sales channels, the company has established professional teams for business distribution, drug agency, OTC promotion, academic promotion, and international trade, with over 3,000 marketing personnel. Sales outlets cover high, medium, and low-end markets across 30 provinces and cities nationwide, and the company is currently building the largest drug distribution center in Shanxi Province.
The company has successively received honors such as the National May Day Labor Award, National Advanced Enterprise for Quality and Efficiency, National Contract-honoring and Credit-worthy Enterprise, China's Most Growth-oriented Enterprise, National Top Ten Corporate Culture Brands, and National Leading Enterprise in Poverty Alleviation.
Adhering to the philosophy of "Dedicated to medicine, benefiting humanity," the company continuously refines its products, optimizes services, strengthens its enterprise, and expands its brand, striving to build a "Global Yabao, Century-old Yabao" and determined to make greater contributions to human health.